CHEMFAB2025-01-012025-03-31CHEMFAB2025-03-31CHEMFAB2024-03-31CHEMFAB2024-04-012025-03-31CHEMFAB2025-01-012025-03-31in-capmkt:OtherExpenses1MemberCHEMFAB2025-01-012025-03-31in-capmkt:OtherExpenses2MemberCHEMFAB2024-04-012025-03-31in-capmkt:OtherExpenses1MemberCHEMFAB2024-04-012025-03-31in-capmkt:OtherExpenses2MemberCHEMFAB2025-01-012025-03-31in-capmkt:ReportableSegments1MemberCHEMFAB2025-01-012025-03-31in-capmkt:ReportableSegments2MemberCHEMFAB2024-04-012025-03-31in-capmkt:ReportableSegments1MemberCHEMFAB2024-04-012025-03-31in-capmkt:ReportableSegments2MemberCHEMFAB2025-01-012025-03-31in-capmkt:ReportableSegments1MemberCHEMFAB2025-01-012025-03-31in-capmkt:ReportableSegments2MemberCHEMFAB2024-04-012025-03-31in-capmkt:ReportableSegments1MemberCHEMFAB2024-04-012025-03-31in-capmkt:ReportableSegments2MemberCHEMFAB2025-01-012025-03-31in-capmkt:ReportableSegments1MemberCHEMFAB2025-03-31in-capmkt:ReportableSegments1MemberCHEMFAB2025-01-012025-03-31in-capmkt:ReportableSegments2MemberCHEMFAB2025-03-31in-capmkt:ReportableSegments2MemberCHEMFAB2025-01-012025-03-31in-capmkt:ReportableSegments1MemberCHEMFAB2025-03-31in-capmkt:ReportableSegments1MemberCHEMFAB2025-01-012025-03-31in-capmkt:ReportableSegments2MemberCHEMFAB2025-03-31in-capmkt:ReportableSegments2MemberCHEMFAB2025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1CHEMFAB2025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2CHEMFAB2024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1CHEMFAB2024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2CHEMFAB2025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares541269CHEMFABNOTLISTEDINE783X01023CHEMFAB ALKALIS LIMITEDMain BoardEquity2024-04-012025-03-312025-05-142025-05-07INRLakhsQuarterlyFourth quarterMulti segment2025-05-1412:00:002025-05-1419:15:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated92324200013762000937004000278434000011592000613500001565600010607000043850800091161000025394000-98877000-73483000102250008155000183800000-918630000000-918630002347000-8951600014363700010-6.41-6.3800-6.41-6.38Notes: <BR> 1. The Statement of Consolidated audited financial results comprises of the financial results of Chemfab Alkalis Limited (CAL) (the Parent Company) and Chemfab Alkalis Karaikal Limited (CAKL) (the Subsidiary) (together referred to as the Group). These financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Parent Company at their meeting held on 14 May 2025. <BR> 2. During the current year ended 31 March 2025, the Parent Company had allotted 1,37,100 Equity shares of Rs. 10 each upon exercise of Employee stock options by the eligible employees under Employee's Stock Option Scheme CAESOS 2020. Consequently, the paid up share capital of the Parent Company had increased from Rs. 1,422.66 Lakhs to Rs. 1,436.37 Lakhs during the year ended 31 March 2025 <BR> 3. The Group has identified its reportable segments in accordance with Ind AS 108 - Operating Segments. Accordingly, two reportable segments i.e. Chemicals and Related Products and PVC - O Pipes <BR> 4. During the current year the subsidiary company has written off certain investments amounting to Rs. 988.77 Lakhs identified towards Caustic soda Plant project basis judgement that the future economic benefits of the expenditure incurred is unlikely to accrue to the company and hence could not be capitalised. <BR> 5.The board of directors of the Parent Company in their meeting held on 14 May 2025 have approved the sale of 667.49 acres of land at Salt Division 2 of Chemical division which is expected to be consummated during FY 2025-2026. <BR> 6. During the year the subsidiary company has, considering the current business dynamics of product realisation and demand, competition, commercial viability decided to sell parts of assets held in capital work in progress towards Caustic Soda Plant aggregating to Rs. 1,804.47 lakhs which is classified as Asset held for Sale as at 31 March 2025. The subsidiary company has assessed and concluded that no further adjustments are required to the carrying value of assets held for sale. <BR> 7. The Statement of Consolidated Assets and Liabilities as at 31 March 2025 and the Statement of Consolidated Cash Flows are provided as annexures to this Statement. <BR> 8. The Board of Directors of the Parent Company has recommended a final dividend of 12.50 % (Rs. 1.25 per Equity Share of Rs. 10 each) which is subject to the approval of the shareholders in the forthcoming Annual General Meeting of the Parent Company. <BR> 9. The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between audited figures of the full financial year ended 31 March 2025 and published year to date figure upto third quarter ended 31 December 2024 and audited figures of the full financial year ended 31 March 2024 and published year to date figures upto third quarter ended 31 December 2023 respectively.2024-04-012025-03-31AuditedConsolidated3343743000711790003414922000102120400073523000-98201000255052000492500003633130001654958000331909900095823000-98877000-30540003781000028539000663490000-694030000000-694030003843000-65560000143637000103656244000-4.86-4.8400-4.86-4.84Direct Manufacturing Expenses - Power, Fuel & Others312000000Other Expenses126508000Direct Manufacturing Expenses - Power, Fuel & Others1188023000Other Expenses46693500030322510003593720000138678000954000019712000206660002298490002437390004024555000271838000162581000207695000470100002247000055870004251200002646950009616530002320170000521822500014363700036562440003799881000379988100063795000019606000657556000268020001200000069635800018740000081000003143940003224940004641300055630700013621600016090000133730007219860000014183440005218225000Notes: <BR> 1. The Statement of Consolidated audited financial results comprises of the financial results of Chemfab Alkalis Limited (CAL) (the Parent Company) and Chemfab Alkalis Karaikal Limited (CAKL) (the Subsidiary) (together referred to as the Group). These financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Parent Company at their meeting held on 14 May 2025. <BR> 2. During the current year ended 31 March 2025, the Parent Company had allotted 1,37,100 Equity shares of Rs. 10 each upon exercise of Employee stock options by the eligible employees under Employee's Stock Option Scheme CAESOS 2020. Consequently, the paid up share capital of the Parent Company had increased from Rs. 1,422.66 Lakhs to Rs. 1,436.37 Lakhs during the year ended 31 March 2025 <BR> 3. The Group has identified its reportable segments in accordance with Ind AS 108 - Operating Segments. Accordingly, two reportable segments i.e. Chemicals and Related Products and PVC - O Pipes <BR> 4. During the current year the subsidiary company has written off certain investments amounting to Rs. 988.77 Lakhs identified towards Caustic soda Plant project basis judgement that the future economic benefits of the expenditure incurred is unlikely to accrue to the company and hence could not be capitalised. <BR> 5.The board of directors of the Parent Company in their meeting held on 14 May 2025 have approved the sale of 667.49 acres of land at Salt Division 2 of Chemical division which is expected to be consummated during FY 2025-2026. <BR> 6. During the year the subsidiary company has, considering the current business dynamics of product realisation and demand, competition, commercial viability decided to sell parts of assets held in capital work in progress towards Caustic Soda Plant aggregating to Rs. 1,804.47 lakhs which is classified as Asset held for Sale as at 31 March 2025. The subsidiary company has assessed and concluded that no further adjustments are required to the carrying value of assets held for sale. <BR> 7. The Statement of Consolidated Assets and Liabilities as at 31 March 2025 and the Statement of Consolidated Cash Flows are provided as annexures to this Statement. <BR> 8. The Board of Directors of the Parent Company has recommended a final dividend of 12.50 % (Rs. 1.25 per Equity Share of Rs. 10 each) which is subject to the approval of the shareholders in the forthcoming Annual General Meeting of the Parent Company. <BR> 9. The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between audited figures of the full financial year ended 31 March 2025 and published year to date figure upto third quarter ended 31 December 2024 and audited figures of the full financial year ended 31 March 2024 and published year to date figures upto third quarter ended 31 December 2023 respectively.Chemicals and related Products607896000PVC-O Pipes315346000Chemicals and related Products2029238000PVC-O Pipes13145050009232420003343743000009232420003343743000Chemicals and related Products-4399000PVC-O Pipes31687000Chemicals and related Products-231007000PVC-O Pipes30490100027288000738940001565600049250000-13762000-711790002539400095823000Chemicals and related Products3161708000PVC-O Pipes158582100047475290004706960005218225000Chemicals and related Products354682000PVC-O Pipes2181340005728160008455280001418344000Notes: <BR> 1. The Statement of Consolidated audited financial results comprises of the financial results of Chemfab Alkalis Limited (CAL) (the Parent Company) and Chemfab Alkalis Karaikal Limited (CAKL) (the Subsidiary) (together referred to as the Group). These financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Parent Company at their meeting held on 14 May 2025. <BR> 2. During the current year ended 31 March 2025, the Parent Company had allotted 1,37,100 Equity shares of Rs. 10 each upon exercise of Employee stock options by the eligible employees under Employee's Stock Option Scheme CAESOS 2020. Consequently, the paid up share capital of the Parent Company had increased from Rs. 1,422.66 Lakhs to Rs. 1,436.37 Lakhs during the year ended 31 March 2025 <BR> 3. The Group has identified its reportable segments in accordance with Ind AS 108 - Operating Segments. Accordingly, two reportable segments i.e. Chemicals and Related Products and PVC - O Pipes <BR> 4. During the current year the subsidiary company has written off certain investments amounting to Rs. 988.77 Lakhs identified towards Caustic soda Plant project basis judgement that the future economic benefits of the expenditure incurred is unlikely to accrue to the company and hence could not be capitalised. <BR> 5.The board of directors of the Parent Company in their meeting held on 14 May 2025 have approved the sale of 667.49 acres of land at Salt Division 2 of Chemical division which is expected to be consummated during FY 2025-2026. <BR> 6. During the year the subsidiary company has, considering the current business dynamics of product realisation and demand, competition, commercial viability decided to sell parts of assets held in capital work in progress towards Caustic Soda Plant aggregating to Rs. 1,804.47 lakhs which is classified as Asset held for Sale as at 31 March 2025. The subsidiary company has assessed and concluded that no further adjustments are required to the carrying value of assets held for sale. <BR> 7. The Statement of Consolidated Assets and Liabilities as at 31 March 2025 and the Statement of Consolidated Cash Flows are provided as annexures to this Statement. <BR> 8. The Board of Directors of the Parent Company has recommended a final dividend of 12.50 % (Rs. 1.25 per Equity Share of Rs. 10 each) which is subject to the approval of the shareholders in the forthcoming Annual General Meeting of the Parent Company. <BR> 9. The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between audited figures of the full financial year ended 31 March 2025 and published year to date figure upto third quarter ended 31 December 2024 and audited figures of the full financial year ended 31 March 2024 and published year to date figures upto third quarter ended 31 December 2023 respectively.49250000-1116920003815000000-8245000000009361400036331300000000-861000000000000389194000386140000000619760007492600039909000000000000232790001133898000000000000000000000133490000237410000-8598600000010410000000007080000006465000001731900000-49213000587228000126458000012645800068408000194866000Remeasurement of net defined benefit liability4095000Fair value gain on investments in equity instruments designated as at FVTOCI-5550003540000Remeasurement of net defined benefit liability5809000Fair value gain on investments in equity instruments designated as at FVTOCI-2750005534000119300016910000023470003843000AuditedtrueDeloitte Haskins and Sells LLPtrue2027-07-31